Childhood carcinoid tumors: The St Jude Children's Research Hospital experience

Citation
Sl. Spunt et al., Childhood carcinoid tumors: The St Jude Children's Research Hospital experience, J PED SURG, 35(9), 2000, pp. 1282-1286
Citations number
21
Categorie Soggetti
Pediatrics
Journal title
JOURNAL OF PEDIATRIC SURGERY
ISSN journal
00223468 → ACNP
Volume
35
Issue
9
Year of publication
2000
Pages
1282 - 1286
Database
ISI
SICI code
0022-3468(200009)35:9<1282:CCTTSJ>2.0.ZU;2-3
Abstract
Background/Purpose: To better characterize childhood carcinoid tumors, the authors reviewed the clinical presentation, treatment, and outcomes of pedi atric patients with these rare tumors. Methods: A retrospective review was conducted of medical records and pathol ogic materials of all children with carcinoid tumors treated at St Jude Chi ldren's Research Hospital between December 1977 and March 1999. Results: Eight patients (median age, 12.7 years) were identified; 2 were bo ys, and 7 were white. Primary tumor sites were the appendix (n = 5), small intestine (n = 1), bronchus (n = 1), and 1 unknown site. In 7 cases, carcin oid tumor was not suspected at the time the tumor was identified. Seven pat ients had localized disease; 5 remain disease-free after complete resection , and 2, whose carcinoid tumors were identified incidentally, died of metas tatic mucinous adenocarcinoma of the colon. One patient who presented with symptoms of carcinoid syndrome had metastatic disease that responded poorly to cytotoxic chemotherapy and remains alive with active disease. Conclusions: Although most pediatric carcinoid tumors arise in the appendix , these tumors also occur in other primary sites. Clinical awareness and ea rly diagnosis are important factors in preventing morbidity and mortality. Outcomes are excellent for patients with localized disease that is complete ly resected, but those with metastatic disease fare poorly. New therapeutic strategies are needed for these patients. J Pediatr Surg 35:1282-1286. Cop yright (C) 2000 by W.B, Saunders Company.